2 unknown. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Unknown 2 |
Follow Lymphangiomyoma: new trials by email Literature Review of Lymphangiomyoma trials Research Report on Lymphangiomyoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effect of Loratadine in Lymphangioleiomyomatosis Loratadine, Placebo 10mg/day added to rapamycin for 12 months - Lymphangioleiomyomatosis | Phase 2 | Unknown | Institut d'Investigació Biomèdica de Bellvitge | 62 | 2021-11-01 | 2022-01-27 |
| Trial of Efficacy and Safety of Sirolimus in Tuberous Sclerosis and LAM sirolimus - Tuberous Sclerosis, Lymphangioleiomyomatosis | Phase 2 | Unknown | Cardiff University | 14 | 2005-10-01 | 2008-04-30 |
Lymphangioleiomyomatosis (2) · Tuberous Sclerosis (1)
Hemic and Lymphatic Diseases (2) · Immune System Diseases (2) · Immunoproliferative Disorders (2) · Lymphatic Diseases (2) · Lymphoproliferative Disorders (2) · Neoplasm, Lymphatic Tissue (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Neoplasms, Connective and Soft Tissue (2) · Perivascular Epithelioid Cell Neoplasms (2) · Congenital Abnormalities (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Genetic Diseases, Inborn (1) · Hamartoma (1)
Loratadine (1) · Sirolimus (1)
Cardiff University (1) · Institut d'Investigació Biomèdica de Bellvitge (1)
Spain (1) · United Kingdom (1)
Julian R Sampson, DM (1) · Maria Molina-Molina, MD, PhD (1)